Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 5:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 2,092 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Alzheimer Disease Clear all
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation

NCT05557409
View directory record Official record
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation
Interventions
AXS-05, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
65 Years to 90 Years
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
53
States / cities
Peoria, Arizona • Tempe, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 30, 2026, 5:02 AM EDT
Completed Not applicable Interventional

Telephone Acceptance and Commitment Therapy Intervention for Caregivers of Adults With ADRD

NCT04780178
View directory record Official record
Conditions
Anxiety, Caregiver Burden
Interventions
Telephone Acceptance and Commitment Therapy Intervention for Caregivers of Adults with Alzheimer's Disease and Related Dementias
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
21 Years to 95 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Sep 30, 2026, 5:02 AM EDT
Active, not recruiting Early Phase 1 Interventional

Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia

NCT04075435
View directory record Official record
Conditions
Alzheimer Disease, Anxiety, Agitation,Psychomotor, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
Interventions
high CBD/low THC sublingual solution
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
55 Years to 90 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 30, 2026, 5:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Amyloid Plaque and Tangle Imaging in Aging and Dementia

NCT00355498
View directory record Official record
Conditions
Memory Disorders, Alzheimer's Disease
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
30 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Sep 30, 2026, 5:02 AM EDT
Active, not recruiting Not applicable Interventional

Stress and Blood Pressure Management for Caregivers

NCT05734638
View directory record Official record
Conditions
Hypertension, Stress, Psychological
Interventions
MIM-DASH, MIM Only, DASH Only
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
40 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 30, 2026, 5:02 AM EDT
Completed Phase 2 Interventional

Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)

NCT00151333
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
SRA-333
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
3
States / cities
Phoenix, Arizona • Fort Lauderdale, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 4, 2009 · Synced Sep 30, 2026, 5:02 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease

NCT02245737
View directory record Official record
Conditions
Alzheimer´s Disease
Interventions
Lanabecestat, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
55 Years to 85 Years
Enrollment
2,218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
77
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Sep 30, 2026, 5:02 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Designing Care Management for Hospice Transitions for Persons Living With Advanced Dementia

NCT07182357
View directory record Official record
Conditions
Alzheimer Disease and Related Dementias
Interventions
Dementia Care Management Checklist for Hospice Transitions
Behavioral
Lead sponsor
New York University
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 30, 2026, 5:02 AM EDT
Terminated Not applicable Interventional Results available

Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease

NCT01082965
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Donepezil, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
8
States / cities
San Francisco, California • Baltimore, Maryland • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2013 · Synced Sep 30, 2026, 5:02 AM EDT
Completed No phase listed Observational

Sleep Disordered Breathing and Alzheimer's Disease Biomarkers in Normal Aging and Mild Cognitive Impairment

NCT03912571
View directory record Official record
Conditions
Sleep Disorder
Interventions
Structural 3T MRI, MRI Based Perfusion Imaging, VR-CO2 MRI Scans
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
55 Years to 90 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Sep 30, 2026, 5:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Florbetapir Calibration to the Centiloid Scale

NCT02120664
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Florbetapir (18F), 11C-PiB
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Sep 30, 2026, 5:02 AM EDT
Completed Not applicable Interventional

Genes, Exercise, Memory and Neurodegeneration

NCT01021644
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
aerobic exercise-training, stretch exercise
Behavioral
Lead sponsor
Howard University
Other
Eligibility
60 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Sep 30, 2026, 5:02 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Nutritional and Pharmacological Intervention for Body, Brain, and Longevity Effects (NIBBLE)

NCT06682767
View directory record Official record
Conditions
Cerebral Blood Flow, APOE 4
Interventions
FMD1 (LNT22-017-1), Rapamycin, Placebo
Dietary Supplement · Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
45 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 30, 2026, 5:02 AM EDT
Recruiting Not applicable Interventional

Michigan Healthy Mom (MI-MOM) Pregnancy Improvement Web Application Trial

NCT07213284
View directory record Official record
Conditions
Pregnancy, Pregnancy, Complications, Pregnancy Outcomes
Interventions
MI MOM App
Behavioral
Lead sponsor
Michigan State University
Other
Eligibility
18 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
8
States / cities
Corunna, Michigan • Flint, Michigan • Gaylord, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Sep 30, 2026, 5:02 AM EDT
Completed Phase 2 Interventional Results available

Cognitive Decline and Alzheimer's Disease in the Dallas Lifespan Brain Study

NCT04080544
View directory record Official record
Conditions
Alzheimer Disease, Cognitive Decline
Interventions
[18F]AV-1451, Positron Emission Tomography
Drug · Procedure
Lead sponsor
Neil M Rofsky, MD, MHA
Other
Eligibility
38 Years to 96 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Sep 30, 2026, 5:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neurotrack Test Validation Protocol

NCT02608021
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
60 Years to 85 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 20, 2019 · Synced Sep 30, 2026, 5:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dimebon (PF-01913539)-Digoxin Drug-Drug Interaction Study In Healthy Subjects

NCT00831506
View directory record Official record
Conditions
Alzheimer Disease, Huntington Disease
Interventions
digoxin, dimebon
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 12, 2009 · Synced Sep 30, 2026, 5:02 AM EDT
Terminated Phase 2Phase 3 Interventional

Study to Evaluate Coconut Oil for Alzheimer's Disease

NCT01883648
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Coconut Oil Beverage, Placebo Beverage
Drug · Other
Lead sponsor
University of South Florida
Other
Eligibility
55 Years to 90 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Sep 30, 2026, 5:02 AM EDT
Completed Phase 2 Interventional Results available

A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease

NCT03118947
View directory record Official record
Conditions
Agitation and Aggression in Alzheimer's Disease
Interventions
Pimavanserin
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
50 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
17
States / cities
Costa Mesa, California • Fresno, California • Fullerton, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Sep 30, 2026, 5:02 AM EDT
Completed Phase 2 Interventional

Treating Behavioral Disturbances in Individuals With Dementia

NCT00073658
View directory record Official record
Conditions
Dementia
Interventions
Citalopram, Risperidone
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
50 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Sep 30, 2026, 5:02 AM EDT
Completed Phase 2 Interventional Results available

Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease

NCT00722046
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PF-04360365 0.1 mg/kg, PF-04360365 0.5 mg/kg, PF-04360365 1 mg/kg, Placebo, PF-04360365 3 mg/kg, PF-04360365 8.5 mg/kg
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
15
States / cities
Peoria, Arizona • Phoenix, Arizona • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 30, 2026, 5:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects

NCT00439010
View directory record Official record
Conditions
Alzheimers Disease
Interventions
[123I] AV 39
Drug
Lead sponsor
Molecular NeuroImaging
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 24, 2008 · Synced Sep 30, 2026, 5:02 AM EDT
Terminated No phase listed Observational

Autonomous Navigating Robot for Detecting Falls and Risk of Falls in Nursing Home Residents With Alzheimer Disease/ADRD - Feasibility Study

NCT07451223
View directory record Official record
Conditions
Fall in Nursing Home
Interventions
Not listed
Lead sponsor
Vigorous Mind, Inc.
Industry
Eligibility
65 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 30, 2026, 5:02 AM EDT
Completed Phase 3 Interventional Results available

Apathy in Dementia Methylphenidate Trial 2

NCT02346201
View directory record Official record
Conditions
Apathy, Alzheimer's Disease
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
9
States / cities
Phoenix, Arizona • Little Rock, Arkansas • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Sep 30, 2026, 5:02 AM EDT